Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Scheiner, B; Kang, B; Balcar, L; Radu, IP; Reiter, FP; Adžić, G; Guo, J; Gao, X; Yuan, X; Cheng, L; Gorgulho, J; Schultheiss, M; Peeters, F; Hucke, F; Ben, Khaled, N; Piseddu, I; Philipp, A; Sinner, F; D'Alessio, A; Pomej, K; Saborowski, A; Bathon, M; Schwacha-Eipper, B; Zarka, V; Lampichler, K; Nishida, N; Lee, PC; Krall, A; Saeed, A; Himmelsbach, V; Tesini, G; Huang, YH; Vivaldi, C; Masi, G; Vogel, A; Schulze, K; Trauner, M; Djanani, A; Stauber, R; Kudo, M; Parikh, ND; Dufour, JF; Prejac, J; Geier, A; Bengsch, B; von, Felden, J; Venerito, M; Weinmann, A; Peck-Radosavljevic, M; Finkelmeier, F; Dekervel, J; Ji, F; Wang, HW; Rimassa, L; Pinato, DJ; Bouattour, M; Chon, HJ; Pinter, M.
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.
Hepatology. 2025; 81(6):1714-1727
Doi: 10.1097/HEP.0000000000001163
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Stauber Rudolf
- Trauner Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND AND AIMS: The outcome of patients with HCC who achieved complete response (CR) to immune-checkpoint inhibitor (ICI)-based systemic therapies is unclear. APPROACH AND RESULTS: Retrospective study of patients with HCC who had CR according to modified Response Evaluation Criteria in Solid Tumors (CR-mRECIST) to ICI-based systemic therapies from 28 centers in Asia, Europe, and the United States. Of 3933 patients with HCC treated with ICI-based noncurative systemic therapies, 174 (4.4%) achieved CR-mRECIST, and 97 (2.5%) had CR according to RECISTv1.1 (CR-RECISTv1.1) as well. The mean age of the total cohort (male, 85%; Barcelona-Clinic Liver Cancer-C, 70%) was 65.9±9.8 years. The majority (83%) received ICI-based combination therapies. Median follow-up was 32.2 (95% CI: 29.9-34.4) months. One- and 3-year overall survival rates were 98% and 86%. One- and 3-year recurrence-free survival rates were excellent in patients with CR-mRECIST-only and CR-RECISTv1.1 (78% and 55%; 70% and 42%). Among patients who discontinued ICIs for reasons other than recurrence, those who received immunotherapy for ≥6 months after the first mRECIST CR had a longer recurrence-free survival than those who discontinued immunotherapy earlier ( p =0.008). Of 9 patients who underwent curative surgical conversion therapy, 8 (89%) had pathological CR (CR-RECISTv1.1, n= 2/2; CR-mRECIST-only, n= 6/7). CONCLUSIONS: Overall survival and recurrence-free survival of patients with CR-mRECIST-only and CR-RECISTv1.1 were excellent, and 6 of 7 patients with CR-mRECIST-only who underwent surgical conversion therapy had pathological CR. Despite potential limitations, these findings support the use of mRECIST in the context of immunotherapy for clinical decision-making. When considering ICI discontinuation, treatment for at least 6 months beyond CR seems advisable.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Male - administration & dosage
- Liver Neoplasms - mortality, drug therapy, therapy, pathology
- Female - administration & dosage
- Carcinoma, Hepatocellular - mortality, drug therapy, therapy, pathology
- Aged - administration & dosage
- Retrospective Studies - administration & dosage
- Immune Checkpoint Inhibitors - therapeutic use
- Middle Aged - administration & dosage
- Immunotherapy - methods
- Response Evaluation Criteria in Solid Tumors - administration & dosage
- Treatment Outcome - administration & dosage
- Neoplasm Recurrence, Local - administration & dosage
- Survival Rate - administration & dosage
- Find related publications in this database (Keywords)
- immune checkpoint inhibitor
- liver cancer
- RECIST
- systemic therapy